ARKK - Editas Medicine: Editing The Way Toward A Potential 10 Bagger

• The field of gene editing remains in its infancy with multiple players jockeying for position.
• The concept is to use the latest in technology to "fix" the genetic abnormality by repairing with a non-defective gene.
• The technology is now evolving to human trials that will shed light on the long-term validity of the therapy.
• Editas is a well-entrenched company that stands to benefit if the trials go as expected.

For further details see: